Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Legacy Healthcare aims to upend alopecia areata treatment with a botanical drug

By Brian Buntz | August 15, 2023

plant under a microscope

Cross sections of plant stem under microscope view [tonaquatic/Adobe Stock]

Imagine a world where botanical drugs could shape the future of medical treatment. Saad Harti, CEO of Swiss company Legacy Healthcare, doesn’t just imagine it; he’s on a mission to make it a reality. With an initial focus on alopecia areata in children and adolescents, Legacy Healthcare believes the plant extract Coacillium could be a blockbuster, given its promise as alopecia areata treatment.

As he put it, it’s all about the “unique assembly of the right plants.” Coacillium contains four: Allium cepa L. (onion), Citrus limon (L.) (lemon), Theobroma cacao (cocoa) and Paullinia cupana Kunth (guarana). The composition, which includes a variety of flavonoids, polyphenols and methylxanthines, has been linked with reversing immuno-inflammatory reactions in hair follicles and adjacent dermal tissues.

Hopes and concerns surrounding JAK inhibitors

Janus Kinase inhibitors (JAK) have recently made strides in treating alopecia areata, which causes unexpected patchy hair loss. In 2022, both the FDA and the European Medicines Agency approved Eli Lilly’s baricitinib, the first JAK inhibitor to win approval in adults battling severe alopecia areata. In June 2023, Pfizer’s kinase inhibitor ritlecitinib won approval for individuals aged 12 and up with severe alopecia areata.

JAK inhibitors are, however, not without risks. Both Baricitinib and ritlecitinib carry black box warnings describing an elevated risk of serious infections, malignancies, thrombosis and major adverse cardiovascular events.

Coacillium, a botanical alopecia areata treatment

Saad Harti

Saad Harti

In developing Coacillium the company aims not only to bring the botanical drug to patients with alopecia areata, but also to show other pharma companies the potential that botanical drugs overall have. “We belong to this industry,” Harti stated, “We’re not hippies living in a tent somewhere.”

Botanical drugs like Coacillium “can achieve exactly what a synthetic drug does” with outcomes that are “probably as good or even better” than conventional synthetic pharmaceuticals.

Results of the recent RAAINBOW Phase 2/3 trial were promising with the trial hitting primary and key secondary endpoints. In particular, Coacillium was associated with improvements in hair regrowth based on the Severity of Alopecia Tool  (SALT) score when compared to placebo. Some 96% of responders continued to show improvement even after the treatment was discontinued.

The side effect profile of JAK inhibitors limits their use to severe cases. While pleased that a treatment option is available, Legacy Healthcare sees an opening. JAK inhibitors are a “great advance for 10% of the patient population,” Harti said. “The majority of the population — the 90% or more — don’t have the severity of the disease that would make them eligible for such a therapy.”

The growing landscape of botanical pharmaceuticals

Legacy Healthcare isn’t alone in its focus on botanical drugs. Other noteworthy examples include GW Research, which won FDA approval for a cannabis derivative in 2018 to treat a severe form of epilepsy. Jazz Pharmaceuticals acquired the company in 2021. Several plant-derived anticancer drugs have also won FDA approval, including Taxol/Paclitaxel, a compound discovered in the Pacific Yew tree (Taxus brevifolia).

The public has long had a fascination with herbal therapies — a trend that has accelerated in recent decades. “We’re all taking care of ourselves, trying to avoid potential toxins. This is a mega trend,” Harti said.

The promise of AI in botanical drug development

In the future, Harti sees the growing interest in AI as a boon for the development of botanical drugs. “Just picture a scenario where the ambition isn’t merely to combat a singular ailment as most pharmaceutical approaches do, but rather, the aim is to tackle a multitude of diseases – say, 20 diverse conditions – simultaneously,” Harti said.

Accomplishing such an objective would pose immense challenges from a data complexity perspective.  “It’s not something that can be achieved by merely having a team of experts meticulously comb through scientific databases like PubMed or explore plant biology research,” he said.

AI can play a role in creating an atlas of druggable targets for individual diseases to help with the discovery process of botanical drugs. “Beyond discovery, the clinical development of a botanical drug is identical to a synthetic agent,” Harti said.

While the development of botanical drugs broadly aligns in many respects with the development of synthetic agents, the true challenge lies in manufacturing, Harti said.

Given AI’s prowess in analyzing vast datasets, spot patterns and forecast outcomes, AI could help botanical drug developers address the manufacturing variability in botanical drugs. “With synthetic agents, you know that every single drug you make will be the same,” Harti said. “It’s more difficult with biologics, but still, there are a lot of similarities with synthetic drugs.” But with botanical drugs, Harti said, “you can take everything you know [about drug manufacturing] and throw it in the bin because plants are unique.” Researchers, for instance, could compare individual apples from the same tree with mass spectrometry and see that their composition is different.


Filed Under: clinical trials, Dermatology, Drug Discovery, machine learning and AI
Tagged With: AI in Pharma, Alopecia Areata, botanical drug manufacturing, botanical drugs, Coacillium, JAK inhibitors, Legacy Healthcare
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Takeda
TAK-279, an oral small-molecule TYK2 inhibitor offering the convenience of a once-daily pill and biologic-like clinical responses
AbbVie 770 logo
Upadacitinib shows promising results in ongoing phase 3 atopic dermatitis studies
Sun Pharma
FDA places clinical hold on Sun Pharma’s dermatology drug as a result of blood clot risk
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE